| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 01/25/2001 | WO2001005834A1 Human tumor necrosis factor receptors tr13 and tr14 |
| 01/25/2001 | WO2001005802A1 Antisense modulation of fadd expression |
| 01/25/2001 | WO2001005776A1 Aminothiazole derivatives and their use as crf receptor ligands |
| 01/25/2001 | WO2001005770A1 Benzimidazolone derivatives and their use as phosphodiesterase inhibitors |
| 01/25/2001 | WO2001005756A1 3-arylsulfonyl-2-(substituted methyl)propanoic acid derivates as matrix metalloproteinase inhibitors |
| 01/25/2001 | WO2001005749A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| 01/25/2001 | WO2001005744A1 Novel aminobenzophenones |
| 01/25/2001 | WO2001005397A1 Procyanidin oligomers inhibiting matrix metalloproteinases and medicine having effective composition of the same |
| 01/25/2001 | WO2001005388A2 Use of a fatty derivative for the treatment of external secretiondisorders |
| 01/25/2001 | WO2000058473A3 Nucleic acids including open reading frames encoding polypeptides; 'orfx' |
| 01/25/2001 | WO2000056360A3 Vaccine against antigens from bacteriae |
| 01/25/2001 | WO2000044740A3 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
| 01/25/2001 | DE19934585A1 Treatment of dermatological disorders, e.g. pruritus, herpes simplex infection, psoriasis or acne, using tosyl chloramide salt, e.g. in ointment or gel base |
| 01/25/2001 | CA2381327A1 Human tumor necrosis factor receptors tr13 and tr14 |
| 01/25/2001 | CA2379554A1 Benzimidazolone derivatives and their use as phosphodiesterase inhibitors |
| 01/25/2001 | CA2379489A1 Procyanidin oligomers inhibiting matrix metalloproteinases and medicine having effective composition of the same |
| 01/25/2001 | CA2379316A1 Novel aminobenzophenones |
| 01/25/2001 | CA2379286A1 Aminobenzophenones as inhibitors of il-1.beta. and tnf-.alpha. |
| 01/25/2001 | CA2378026A1 Novel glycosyl sulfotransferases gst-4.alpha., gst-4.beta., and gst-6 |
| 01/25/2001 | CA2376518A1 Conversion of a watson-crick dna to a hoogsteen-paired duplex |
| 01/25/2001 | CA2375458A1 Compositions and methods for the treatment of immune related diseases |
| 01/24/2001 | EP1070727A1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction |
| 01/24/2001 | EP1070710A2 Dithiolan derivatives, their preparation and their therapeutic effect |
| 01/24/2001 | EP1070069A1 Bicyclic hydroxamic acid derivatives |
| 01/24/2001 | EP1070060A1 Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists |
| 01/24/2001 | EP1070058A1 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides |
| 01/24/2001 | EP1069913A1 Gelling ophthalmic compositions containing xanthan gum |
| 01/24/2001 | EP1069885A1 Ophthalmic solution comprising glycogen |
| 01/24/2001 | EP0788513B1 Use of binding agents to cd23 in the treatment of autoimmune diseases |
| 01/24/2001 | CN1281458A Purine compounds having PDE IV inhibitory activity and methods of synthesis |
| 01/24/2001 | CN1281441A Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors |
| 01/24/2001 | CN1281432A Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing same |
| 01/24/2001 | CN1281367A Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
| 01/24/2001 | CN1061052C 11 Beta-aromatic group-4-estraene and acid additive salt application in medicine |
| 01/24/2001 | CN1061044C Tricyclic 5,6-dihydro-9H-pyrazolo [3,4-C]-1,2,4-triaolo [4,3-alpha] pyridines |
| 01/24/2001 | CN1060946C Copiopia health cream and its producing technique |
| 01/23/2001 | US6177544 Collagen-based auxiliary agent for ophthalmic surgery |
| 01/23/2001 | US6177444 Allosteric adenosine receptor modulators |
| 01/23/2001 | US6177428 Treatment of sexual dysfunction; stimulation of endogenous nitrogen monoxide synthesis |
| 01/23/2001 | US6177419 Antioxidant chelate compounds for preventing oxygen free radical-associated diseases in mammals; neuroprotectants, superoxide dismutase (sod), catalase (cat) and/or peroxidase (pod) mimetics |
| 01/23/2001 | US6177401 Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| 01/23/2001 | CA2191790C Biaromatic compounds containing an adamantyl group in para position; pharmaceutical and cosmetic compositions containing them and use thereof |
| 01/18/2001 | WO2001004308A1 Human lim domain proteins |
| 01/18/2001 | WO2001004298A1 Novel physiologically active substance, process for producing the same and use thereof |
| 01/18/2001 | WO2001004124A1 OXATHIEPINO[6,5-b]DIHYDROPYRIDINES, AND RELATED COMPOSITIONS AND METHODS |
| 01/18/2001 | WO2001004118A2 Quinuclidine derivatives and their use as muscarinic m3 receptor ligands |
| 01/18/2001 | WO2001003743A1 Manipulation of tissue or organ type using the notch pathway |
| 01/18/2001 | WO2001003720A2 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/18/2001 | WO2001003696A1 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 01/18/2001 | WO2001003688A2 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 01/18/2001 | WO2001003668A1 Pulmonary delivery of liposome-encapsulated cannabinoids |
| 01/18/2001 | WO2000055180A3 Human lung cancer associated gene sequences and polypeptides |
| 01/18/2001 | WO2000023565B1 Novel neuropilin/growth factor binding and uses thereof |
| 01/18/2001 | CA2379199A1 Oxathiepino[6,5-b]dihydropyridines, and related compositions and methods |
| 01/18/2001 | CA2378989A1 Human lim domain proteins |
| 01/18/2001 | CA2378465A1 Manipulation of tissue or organ type using the notch pathway |
| 01/18/2001 | CA2378179A1 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/18/2001 | CA2377502A1 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 01/18/2001 | CA2341035A1 Pulmonary delivery of liposomal-encapsulated cannabinoids |
| 01/17/2001 | EP1069124A1 2-Benzimidazolylamine compounds as ORL1-receptor agonists |
| 01/17/2001 | EP1069114A2 Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 01/17/2001 | EP1068185A1 Compounds with activity on muscarinic receptors |
| 01/17/2001 | EP1068180A1 Process for alkylating hindered sulfonamides useful in the production of matrix metalloprotenase inhibitors |
| 01/17/2001 | EP1067966A1 OPHTHALMIC COMPOSITION COMPRISING A $g(b)-BLOCKER |
| 01/17/2001 | EP1067907A1 Ocular irrigating solution |
| 01/17/2001 | EP1067838A1 Treatment of respiratory disease and otitis media |
| 01/17/2001 | EP0983258A4 N-hydroxy 4-sulfonyl butanamide compounds |
| 01/17/2001 | EP0771216B1 Methods and compositions for the specific coagulation of tumoral vasculature |
| 01/17/2001 | EP0730590B1 isoxazoline and isoxazole fibrinogen receptor antagonists |
| 01/17/2001 | EP0581959B1 Use of macrolide compounds for eye diseases |
| 01/17/2001 | CN1280619A (Chlamydia trachomatic) genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
| 01/17/2001 | CN1280568A Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| 01/17/2001 | CN1280496A Use of brinzolamide to prevent visual field loss |
| 01/17/2001 | CN1279947A Eye preparation of zinc norfloxacin |
| 01/16/2001 | US6175021 Human non-pancreatic secretory phospholipase a2 (spla2); inhibits release of arachidonic acid to treat septic shock; ((3-(2-amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1h-indol-4 -yl)oxylacetic acid, for example |
| 01/16/2001 | US6174923 Administering ethynyl alanine amino diol compound for treating hypertension |
| 01/16/2001 | US6174714 Lyss |
| 01/16/2001 | CA2314008A1 2-benzimidazolylamine compounds as orl1-receptor agonists |
| 01/16/2001 | CA2021954C Substituted triazolinones, triazolinethiones and triazolinimines as angiotensin ii antagonists |
| 01/11/2001 | WO2001002866A1 Diagnostics and therapeutics for arterial wall disruptive disorders |
| 01/11/2001 | WO2001002567A1 16405 receptor, a g-protein coupled receptor |
| 01/11/2001 | WO2001002398A1 Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them |
| 01/11/2001 | WO2001002388A1 Indole derivatives and their use for the treatment of osteoporosis amongst other applications |
| 01/11/2001 | WO2001002387A1 N-imidazolylmethyl carboxamides as nitric oxide production inhibitors |
| 01/11/2001 | WO2001002381A1 Piperazine derivatives as modulators of chemokine receptor activity |
| 01/11/2001 | WO2001002372A1 Cyclized amino acid derivatives |
| 01/11/2001 | WO2001002369A2 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| 01/11/2001 | WO2001002363A2 N-substituted glycine derivatives |
| 01/11/2001 | WO2001001986A1 Method of reducing neuronal injury or apoptosis |
| 01/11/2001 | WO2001001981A1 Vegf receptor antagonists |
| 01/11/2001 | WO2001001972A2 SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
| 01/11/2001 | WO2001001970A2 New uses potassium channel openers, such as the treatment of epilepsy |
| 01/11/2001 | WO2001001963A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 01/11/2001 | WO2001001962A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 01/11/2001 | WO2000059904A3 Compounds and methods to treat cardiac failure and other disorders |
| 01/11/2001 | WO2000054770A8 Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis |
| 01/11/2001 | WO2000053596A3 Imidazole compounds as histamine h3 ligands |
| 01/11/2001 | WO2000044397A3 Growth of inner ear and monoclonal antibody against utricular epithelium |
| 01/11/2001 | WO2000038667A3 Prostaglandin e agonists for treatment of glaucoma |
| 01/11/2001 | CA2376657A1 Indole derivatives and their use for the treatment of osteoporosis amongst other applications |